Sanara MedTech Inc. (SMTI)

Market Cap	322.50M +11.2%
Revenue (ttm)	109.81M +13.0%
Net Income	-32.01M
EPS	-3.69
Shares Out	9.19M
PE Ratio	n/a
Forward PE	105.59
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,200
Open	35.08
Previous Close	35.06
Day's Range	35.07 - 35.18
52-Week Range	16.05 - 35.34
Beta	1.16
Analysts	Hold
Price Target	35.00 (-0.28%)
Est. Earnings	Nov 11, 2026

About SMTI

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1982
• Employees: 108
• Stock Exchange: NASDAQ
• Ticker Symbol: SMTI
• Website: https://sanaramedtech.com

Financial Performance

In 2025, Sanara MedTech's revenue was $103.12 million, an increase of 18.97% compared to the previous year's $86.67 million. Losses were -$37.56 million, 288.7% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for SMTI stock is "Hold." The 12-month stock price target is $35.0, which is a decrease of -0.28% from the latest price.

Price Target

$35.0

(-0.28% downside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 28, 2026

Data Sources Report a data error